Recipharm, a CDMO, has recently seen an increase in demand for its product Klorokinfosfat RPH Pharma marketed in Sweden by Astimex Pharma. The company has also received questions about the product, which is typically used to treat patients with malaria prophylaxis and rheumatoid arthritis. The interest in this product is due to chloroquine’s antiviral effects, which has potential to be used to treat patients with coronavirus COVID-19 associated pneumonia. Chloroquine has been included b...